NCT05720494View on ClinicalTrials.gov

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 26, 2023

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
Healthy Participants
Interventions
DRUG

JZP441

Oral study drug administered for up to 4 weeks

DRUG

Placebo

Oral placebo administered for up to 4 weeks

Trial Locations (1)

84124

Clinical Site 1, Salt Lake City

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY